Chon K, Larkins E, Chatterjee S, Mishra-Kalyani PS, et al. FDA Approval Summary: Amivantamab for the Treatment of patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. Clin Cancer Res 2023 Apr 6:CCR-22-3713. doi: 10.1158/1078-0432.CCR-22-3713.
PMID: 37022784